Outlook Therapeutics Inc OTLK:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 05/17/24 EDT
7.82quote price arrow up+0.04 (+0.51%)
Volume
752,524
Close
7.78quote price arrow up+0.45 (+6.14%)
Volume
187,970
52 week range
4.00 - 40.60
Loading...
  • Open7.34
  • Day High7.92
  • Day Low7.18
  • Prev Close7.33
  • 52 Week High40.60
  • 52 Week High Date06/06/23
  • 52 Week Low4.00
  • 52 Week Low Date09/08/23

Key Stats

  • Market Cap181.262M
  • Shares Out23.30M
  • 10 Day Average Volume0.00M
  • Dividend-
  • Dividend Yield-
  • Beta0.65
  • YTD % Change-1.27

KEY STATS

  • Open7.34
  • Day High7.92
  • Day Low7.18
  • Prev Close7.33
  • 52 Week High40.60
  • 52 Week High Date06/06/23
  • 52 Week Low4.00
  • 52 Week Low Date09/08/23
  • Market Cap181.262M
  • Shares Out23.30M
  • 10 Day Average Volume0.00M
  • Dividend-
  • Dividend Yield-
  • Beta0.65
  • YTD % Change-1.27

RATIOS/PROFITABILITY

  • EPS (TTM)-3.99
  • P/E (TTM)-1.95
  • Fwd P/E (NTM)-2.29
  • EBITDA (TTM)-47.70M
  • ROE (TTM)-827.71%
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-605.00%
  • Debt To Equity (MRQ)-150.12%

EVENTS

  • Earnings Date08/12/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Outlook Therapeutics Inc

 

Profile

MORE
Outlook Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on developing and commercializing ONS-5010 (LYTENAVA (bevacizumab-vikg)), an ophthalmic formulation of bevacizumab for use in retinal indications. The Company's product candidate, ONS-5010, is developed to be administered as an intravitreal injection for the treatment of wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), and branch retinal vein occlusion (BRVO)....
Ralph Thurman
Independent Executive Chairman of the Board
C. Russell Trenary III
President, Chief Executive Officer, Director
Lawrence Kenyon
Chief Financial Officer, Executive Vice President, Treasurer, Company Secretary, Director
Address
111 S. Wood Avenue, Unit #100
Iselin, NJ
08830
United States

Top Peers

SYMBOLLASTCHG%CHG
GNLX
Genelux Corp
3.65+0.05+1.39%
SGMT
Sagimet Biosciences Inc
4.62-0.13-2.74%
PMVP
PMV Pharmaceuticals Inc
2.10-0.05-2.33%
ALLK
Allakos Inc
1.44-0.01-0.69%
LPTX
Leap Therapeutics Inc
2.63-0.11-4.01%